Robert W. Baird analyst Eric Coldwell maintained a Hold rating on Medpace Holdings (NASDAQ:MEDP) on Wednesday, setting a price target of $160, which is approximately 11.80% below the present share price of $181.4.
Coldwell expects Medpace Holdings to post earnings per share (EPS) of $1.21 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Medpace Holdings, with an average price target of $176.5.
The analysts price targets range from a high of $193 to a low of $160.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $259.97 million and a net profit of $47.6 million. The company's market cap is $6.53 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.0% and a 63.11% success rate.
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.